Lung cancer is the leading cause of cancer death in the United States and worldwide, accounting for over 150,000 deaths per year in the United States and over 1 million deaths per year world-wide. Non-small cell lung cancer accounts for slightly over 80% of all lung cancer cases. Therefore the development of novel targeted therapeutics for non-small cell lung cancer is of great clinical and public health importance. In recent years, the advent of targeted cancer therapies has led to major advances in the prognosis and survival of cancer patients. Our applicant group has contributed to one of the most dramatic of these advances, the deployment of EGFR inhibitors for patients whose lung cancers bear activating EGFR mutations. This has led to significant advances in treatment of such patients, as demonstrated in this last year by several clinical trials. Nevertheless, as shown by the still-grim mortality statistics, the efforts that lie in front of us far exceed the accomplishments that we and other investigators have achieved to date. The goal of this integrated research Program is to advance the scientific underpinnings of targeted therapies for non-small cell lung cancer. Specifically, we will generate and characterize genetically engineered mouse models based on each of the lung cancer kinase targets (EGFR, TBK1 and DDR2). We will then perform in vivo therapeutic efficacy studies using these mouse models and the appropriately matched targeted therapeutics generated in this Program. Lastly, we will perform in vivo chronic treatment studies with the mouse models and molecule inhibitors to determine in vivo mechanisms of acquired resistance.

Public Health Relevance

Lung cancer is the leading cause of cancer death in the US and worldwide, accounting for over 150,000 deaths per year in the US and over 1 million deaths per year world-wide. Non-small cell lung cancer (NSCLC) accounts for slightly over 80% of all lung cancer cases. Core C is the animal core for the Program Project and will assist each project with animal models and in vivo therapeutic studies working toward the overall goal of developing novel targeted therapeutics for NSCLC which would be of great public health importance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA154303-01A1
Application #
8237138
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Project Start
2012-05-11
Project End
2017-04-30
Budget Start
2012-05-11
Budget End
2013-04-30
Support Year
1
Fiscal Year
2012
Total Cost
$87,099
Indirect Cost
$36,531
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Deng, Jiehui; Wang, Eric S; Jenkins, Russell W et al. (2018) CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8:216-233
Terai, Hideki; Kitajima, Shunsuke; Potter, Danielle S et al. (2018) ER Stress Signaling Promotes the Survival of Cancer ""Persister Cells"" Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res 78:1044-1057
Rusan, Maria; Li, Kapsok; Li, Yvonne et al. (2018) Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discov 8:59-73
Adeegbe, Dennis O; Liu, Shengwu; Hattersley, Maureen M et al. (2018) BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res 6:1234-1245
Gannon, Hugh S; Zou, Tao; Kiessling, Michael K et al. (2018) Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun 9:5450
Aguirre, Andrew J; Hahn, William C (2018) Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harb Perspect Med 8:
Rowbotham, S P; Li, F; Dost, A F M et al. (2018) H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Nat Commun 9:4559
Majkowska, Iwona; Shitomi, Yasuyuki; Ito, Noriko et al. (2017) Discoidin domain receptor 2 mediates collagen-induced activation of membrane-type 1 matrix metalloproteinase in human fibroblasts. J Biol Chem 292:6633-6643
Krall, Elsa B; Wang, Belinda; Munoz, Diana M et al. (2017) KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife 6:
Tan, Li; Gurbani, Deepak; Weisberg, Ellen L et al. (2017) Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem 25:838-846

Showing the most recent 10 out of 80 publications